Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. (NASDAQ: GDRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a digital healthcare and medication savings platform. These SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with exhibits covering executive compensation, director arrangements, and key commercial developments.
In its earnings-related Form 8-K filings, GoodRx furnishes press releases that discuss revenue from prescription transactions, subscriptions, and pharma manufacturer solutions, as well as non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Income. These documents also describe capital allocation priorities, including investing for growth, debt repayment, share repurchases, and mergers and acquisitions that align with the company’s strategy.
Other 8-K filings provide detail on governance and compensation matters. For example, GoodRx has reported retention bonus agreements for certain executives, including the structure of cash retention bonuses and repayment conditions tied to employment status. It has also disclosed the transition of an executive officer to a non-employee director role, outlining standard non-employee director compensation, committee retainers, and restricted stock unit awards under its non-employee director compensation program and deferred compensation plan.
Through this page, users can access GoodRx’s SEC filings as they are made available via EDGAR. AI-powered summaries on the platform help explain the contents of complex documents, including 10-K and 10-Q reports, by highlighting key themes such as segment performance, prescription transactions trends, subscription and pharma manufacturer solutions growth, and risk factor disclosures. Filings related to insider and director compensation, as well as current reports on material events, are also accessible, giving investors and researchers a structured view of how GoodRx manages its business, governance, and financial reporting obligations.
GoodRx Holdings, Inc. (GDRX) Chief Accounting Officer Romin Nabiey reported equity award activity on 11/15/2025. He acquired 4,804 shares of Class A common stock upon the vesting and settlement of restricted stock units and then disposed of 1,719 shares at $2.97 per share, typically used to cover taxes. Following these transactions, he directly held 156,492 Class A shares.
The underlying restricted stock unit grant covers 4,804 shares. It vests as to 6.25% of the underlying shares on May 15, 2025, with the remaining 93.75% vesting in approximately equal quarterly installments over the next 15 quarters.
GoodRx Holdings (GDRX) reported an insider transaction by Chief Accounting Officer Romin Nabiey on 11/08/2025. Restricted stock units converted into 12,662 shares of Class A common stock (code M). To cover taxes, 4,531 shares were withheld at $3.11 per share (code F). Following these transactions, Nabiey directly owns 153,407 Class A shares. The filing also shows 75,977 RSUs remaining beneficially owned after the reported activity. Each RSU represents the right to receive one share, with vesting that began on August 8, 2023 and continues in approximately equal quarterly installments thereafter.
GoodRx Holdings, Inc. (GDRX) reported an insider transaction by a director. On 11/08/2025, 21,691 shares of Class A common stock were acquired via the conversion of deferred stock units (transaction code M).
After the transaction, the director beneficially owned 111,025 shares directly and held 43,384 deferred stock units. The filing notes the award vested as to one-third on November 8, 2025, and that deferred stock units will settle upon specified events, including December 31, 2029 or separation from service.
GoodRx Holdings, Inc. reported Q3 revenue of $196.0 million, up slightly year over year, with operating income of $14.6 million and net income of $1.1 million versus $4.0 million a year ago. For the first nine months, revenue was $602.1 million and net income was $25.0 million. Diluted EPS was $0.00 for the quarter and $0.07 year to date. Cash and equivalents were $273.5 million, and term loan principal was $496.3 million.
The revenue mix shifted: prescription transactions were $127.3 million (vs. $140.4 million), pharma manufacturer solutions rose to $43.4 million (vs. $28.1 million), subscriptions were $20.7 million (vs. $21.3 million), and other revenue was $4.6 million (vs. $5.4 million). Monthly Active Consumers were 5.4 million (vs. 6.5 million). Subscription plans were 671,000. The company repurchased 46.9 million shares year to date for $208.9 million, with $81.4 million remaining under the authorization.
Transactions included acquiring VCRx for $30.0 million and, subsequent to quarter-end, ScriptDrop for $13.5 million. Legal accruals included $25.0 million related to an NDCA class action settlement (subject to court approval) and $5.5 million for indemnification. Management estimates a $35.0–$40.0 million 2025 impact to prescription transactions revenue from retail pharmacy and PBM changes and an integrated savings program volume reduction.
GoodRx Holdings, Inc. announced its financial results for the three and nine months ended September 30, 2025. The company furnished a press release as Exhibit 99.1 to provide details.
The information under Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated.
GoodRx (GDRX) director Trevor Bezdek reported equity awards and updated holdings. On 11/02/2025, he received 104,925 restricted stock units (RSUs) at $0 that vest in three equal installments beginning 11/02/2026. He also acquired 33,530 RSUs at $0 that vest in full on the earlier of June 3, 2026 or the 2026 annual meeting, subject to continued service.
Following the transactions, he beneficially owned 160,082 Class A shares directly. Indirect holdings were listed as 2,632,721 shares by TB 2024-2 GRAT and 2,632,721 shares by JB 2024-2 GRAT.
GoodRx Holdings (GDRX) director Scott Wagner filed a Form 4 reporting an award of 3,065 deferred stock units on 10/31/2025 at $0. Each unit represents a contingent right to one share of Class A common stock.
The units vest in substantially equal monthly installments beginning November 30, 2025 and ending December 31, 2025, and will settle upon the earliest of December 31, 2030, Separation from Service, a Change in Control, death, or Disability under the company’s director plan. Following the transaction, Wagner beneficially owned 185,269 shares directly and 182,900 shares indirectly via the Wagner Family Trust.
GoodRx Holdings announced that Co‑Chairman Trevor Bezdek ended his employment and executive officer service upon his employment agreement’s expiration on November 1, 2025, and will continue as a non‑employee Co‑Chairman of the Board.
As a non‑employee director, he will be eligible for the standard program: a $30,000 annual cash retainer for Board service, $10,000 for Nominating and Corporate Governance Committee service, and $75,000 for Co‑Chair of the Board, each pro‑rated for 2025. If serving on the Board as of the annual meeting date, he is also eligible for an annual RSU award valued at $230,000.
In connection with the transition, the Board granted RSUs valued at $420,000 (vesting one‑third annually over three years) and $134,219 (vesting in full on the earlier of June 3, 2026 or the 2026 Annual Meeting), effective November 2, 2025. The RSU share counts were determined using the 30‑day average closing price preceding the grant dates. He may defer cash retainers and RSU settlements under the Deferred Compensation Plan.
GoodRx Holdings (GDRX) — Form 4: Director Douglas Hirsch reported the settlement of restricted stock units into 20,521 shares of Class A common stock on 10/26/2025 under transaction code M. Following the transaction, he directly beneficially owned 231,909 Class A shares and held 41,042 RSUs as derivative securities.
The filing notes that each RSU represents the right to receive one share of Class A common stock. The RSU award vests as to one-third of the underlying shares on each of the first three anniversaries of the grant date, beginning on October 26, 2025. The report also lists indirect holdings through certain grantor retained annuity trusts, with beneficial ownership of one such trust disclaimed.
GoodRx Holdings (GDRX): insider filing shows share class conversion and small sales. On 10/14/2025, affiliated Spectrum funds converted Class B Common Stock into 8,881,362 Class A shares on a one-for-one basis, then Spectrum Equity VII, L.P. made a pro rata distribution of 8,881,362 Class A shares to partners for no consideration. On 10/15/2025, Spectrum VII Investment Managers' Fund and Spectrum VII Co-Investment Fund sold 15,202 and 8,569 Class A shares, respectively, at a weighted average price of $4.0008. After these transactions, each listed fund reported 0 shares beneficially owned.